Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

The Impact of Antibiotic Prophylaxis on Incidence of Post-bronchoscopy Fever and Change of Serum Cytokines

This study has been completed.
Information provided by:
Seoul National University Hospital Identifier:
First received: March 14, 2010
Last updated: July 19, 2011
Last verified: July 2011
Fever can develop after fiberoptic bronchoscopy (FB) in about 2.5 - 16 % of adult patients. We evaluated the impact of oral amoxicillin/clavulanate (AC) on incidence of postbronchoscopic fever and pneumonia.

Condition Intervention Phase
Drug: oral amoxicillin/clavulanate 1g (875/125mg)
Drug: control
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single Blind (Investigator)
Primary Purpose: Prevention
Official Title: The Impact of Antibiotic Prophylaxis on Incidence of Post-bronchoscopy Fever and Change of Serum Cytokines

Resource links provided by NLM:

Further study details as provided by Seoul National University Hospital:

Primary Outcome Measures:
  • The incidence of fever [ Time Frame: 24 hr after bronchoscopy ]
    time frame for body temperature 24hr before and after bronchoscopy every 4hrs

Secondary Outcome Measures:
  • change of serum cytokines level [ Time Frame: before bronchoscopy and 24hr after bronchoscopy ]
    Time frame for cytokine measurement 24hr before brochoscopy - 1hr after bronchosocpy - 24hr after brochoscopy

Enrollment: 241
Study Start Date: April 2008
Study Completion Date: February 2010
Primary Completion Date: January 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
No Intervention: control
control without intervention
Drug: control
no intervention with the same procedure of FB
Active Comparator: Amoxicillin/clavulanate Drug: oral amoxicillin/clavulanate 1g (875/125mg)
oral amoxicillin/clavulanate 1g (875/125mg) on the day of the procedure 30 minutes prior to the FB
Other Name: prophylaxis group

Detailed Description:
For the population being undergone with bronchoscopy, the clinical signs and procedural measures for complication of bronchoscopy and cytokines will be checked.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • adult patients (aged 18 years or older) who underwent FB

Exclusion Criteria:

  • concurrent treatment with antibiotics or systemic corticosteroid
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01089218

Sponsors and Collaborators
Seoul National University Hospital
Study Director: Deog Kyeom Kim, MD. Seoul Metropolitan Government, Seoul National University Boramae Medical Center, 39 Boramae-Gil, Dongjak-Gu, Seoul, Republic of Korea 156-707.
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Deog Kyeom Kim, MD, Seoul Metropolitan Government, Seoul National University Boramae Medical Center Identifier: NCT01089218     History of Changes
Other Study ID Numbers: postFB fever
Study First Received: March 14, 2010
Last Updated: July 19, 2011

Keywords provided by Seoul National University Hospital:
post-bronchoscopy fever

Additional relevant MeSH terms:
Lung Diseases
Respiratory Tract Diseases
Respiratory Tract Infections
Body Temperature Changes
Signs and Symptoms
Anti-Bacterial Agents
Clavulanic Acid
Clavulanic Acids
Amoxicillin-Potassium Clavulanate Combination
Anti-Infective Agents
beta-Lactamase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action processed this record on April 28, 2017